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Summary The factors that determine development of single and multiple primary cutaneous basal cell
carcinomas (BCCs) are unclear. We describe a case-control study firstly, to examine the influence of allelism
at the glutathione S-transferase GSTM1 and GSTTI and cytochrome P450 CYP2D6 loci on susceptibility to
these tumours and, secondly, to identify interactions between genotypes and relevant individual characteristics,
such as skin type and gender. Frequency distributions for GSTM1 genotypes in cases and controls were not
different, although the frequency of GSTM1 A/B was significantly lower (P = 0.048) in the multiple BCCs
than in controls. We found no significant differences in the frequencies of GSTT1 and CYP2D6 genotypes in
cases and controls. Interactions between genotypes were studied by comparing multinomial frequency distribu-
tions in mutually exclusive groups. These identified no differences between cases and controls for combinations
of the putatively high risk GSTM1 null, GSTT1 null, CYP2D6 EM genotypes. Interactions between GSTMI
A/B and the CYP2D6 PM and GSTT1-positive genotypes were also not different. Frequency distributions of
GSTMI A/B with CYP2D6 EM in controls and multiple BCCs were significantly different (P = 0.033). The
proportion of males in the multiple BCC group (61.3%) was greater than in controls (47.0%) and single BCC
(52.2%), and the frequency of the combination GSTM1 null/male gender was significantly greater in patients
with multiple tumours (P = 0.002). Frequency distributions of GSTM1 null/skin type 1 were also significantly
different (P = 0.029) and the proportion of subjects who were GSTM1 null with skin type 1 was greater
(P = 0.009) in the multiple BCC group. We examined the data for interactions between GSTM1 null/skin type
1/male gender by comparing frequency distributions of these factors in the single and multiple BCC groups.
The distributions were almost significantly different (exact P = 0.051). No significant interactions between
GSTT1 null or CYP2D6 EM and skin type 1 were identified. Comparisons of frequency distributions of
smoking with the GSTMI null, GSTTI null and CYP2D6 EM genotypes identified no differences between
patients with single and multiple tumours.
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Basal cell carcinoma of skin (BCC) is the commonest malig-
nancy in Caucasians and its incidence is increasing world-
wide. Indeed, increases of over 10% per year are reported
(Kricker et al., 1993). Ultraviolet radiation (UV) is a critical
causative factor, although the relationship between disease
risk and exposure is complex. Thus, comparison of the dist-
ributions of BCCs and squamous cell cancers (SCCs) shows
that BCCs are more prevalent on the trunk, a site usually
only intermittently exposed, while SCCs are most common
on the more exposed head and neck (Weinstock, 1994;
Karagas and Greenberg, 1995).
Patients with a BCC are at high risk of suffering a further
primary lesion, with studies in American patients showing
that the crude 5 year risk of a new tumour is 50% (Karagas
et al., 1994). Importantly, this figure depends on the number
of tumours already present; in subjects with one tumour the
5 year risk is 27%; in those with ten or more tumours the
risk is 90%. These findings suggest that some subjects are at
an inherently higher risk of this malignancy (Karagas et al.,
1994). However, while inherited factors are important in
Gorlin's syndrome (Farndon et al., 1992), the role of predis-
posing or protective genes in the genesis of sporadic, multiple
BCC is less clear. Karagas et al. (1994) showed that the risk
of further lesions increases with age, male gender and inter-
mittent high exposures to UV. Susceptibility is also related to
individual response to sunlight. Thus, subjects who readily
burn and do not tan (skin type I; Fitzpatrick et al., 1988) are
at greater risk than those who tan easily and never burn (skin
type IV) (Karagas et al., 1994). Other factors that influence
susceptibility to multiple tumours include the effectiveness of
repair of damaged DNA. Thus, Wei et al. (1994) showed that
a reduced capacity to repair a UV-damaged reporter gene is
associated with an increased risk of multiple BCC. We have
shown that allelism at the glutathione S-transferase GSTM1
locus also influences susceptibility to multiple BCC (Heagerty
et al., 1994). The mechanism for this effect is unclear as these
enzymes metabolise a variety of potential carcinogens, in-
cluding lipid and DNA products of UV-induced oxidative
stress (e.g. DNA hydroperoxide). Indeed, their ability to
catalyse the detoxification of 5-hydroxymethyluracil suggests
a role in the repair of DNA damaged by oxidative stress
(Ketterer et al., 1993). GSTM1 enzymes also catalyse the
metabolism of epoxides formed from pollutants such as
polycyclic aromatic hydrocarbons (Ketterer et al., 1993).
GSTM1 genotypes result from combinations of GSTMJ*O,
GSTMI*A and GSTMI*B. GSTMJ*O is deleted, suggesting
that homozygotes will be more susceptible to inflammatory
and/or malignant pathologies. There is evidence from studies
in multiple skin cancers of different histological types and
BCCs (Heagerty et al., 1994) as well as other cancers such as
lung, to support this view (Seidegard et al., 1988; Nakachi et
al., 1993; Strange, 1993).
The polymorphic, theta class, glutathione S-transferase
gene, GSTT1, also catalyses the metabolism of oxidised lipid
and DNA as well as epoxides (Ketterer et al., 1993).
Homozygotes for deleted GSTTJ*O constitute 17% of
Caucasians and, while the consequences are unclear (War-
wick et al., 1994), comparison with GSTM 1 null suggests
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induced damage. In particular, individuals null at both loci
may be especially susceptible to oxidative or chemical stress.
Apart from UV, skin is exposed to chemical carcinogens
whose metabolism depends on the cytochrome P450 super-
gene family (CYP) (Jugert et al., 1994). The products of
many CYP-catalysed reactions are substrates for GSTM 1
and GSTT1, indicating the need for coordinated expression
of these genes to prevent accumulation of carcinogenic reac-
tive oxygenated intermediates. While epidemiological surveys
have not identified a link between BCCs and hydrocarbon
exposure, CYP genes may be relevant in mediating suscep-
tibility to skin cancers, as Wolf et al. (1992) found increased
frequency of CYP2D6 mutant alleles in patients with malig-
nant melanoma.
We describe a case-control study to determine the
relevance of GSTM1, GSTT1 and CYP2D6 genotypes in
mediating susceptibility to single and multiple BCC. As the
effects of genotypes may be influenced by sex, skin type, eye
colour and smoking, interactions between genotypes and
these factors have been studied.
Materials and methods
Patients
A total of 737 unrelated Caucasian patients with his-
tologically proven BCC were recruited between November
1991 and December 1994 from dermatology out-patient
clinics in the Midlands and South of England; Staffordshire
(North Staffordshire Hospital, Stafford General Hospital),
Cornwall (Royal Cornwall Hospitals) and Hampshire (Royal
South Hants Hospital). A total of 481 patients (52.2% males,
mean age 67 years) suffered a single tumour and 256 patients
(61.3% males, mean age 70 years) more than one tumour
(between 2 and 50 tumours per patient). Original hair colour,
eye colour and skin type (types 1-5) (Fitzpatrick et al., 1988)
were recorded at sample collection. A smoking history was
also obtained allowing subjects to be classified as current
smokers, ex-smokers or never smokers. Four hundred and
thirty-five of these patients constitute the BCC case group
described by Heagerty et al. (1994). Data on GSTMI
genotype frequencies in these subjects were included in the
present study. Genotype frequencies in the original case
group and the further 302 subjects recruited between October
1993 and December 1994 were not different. A control group
comprising 563 British Caucasians (47.0% males, mean age
70 years) from these centres, who were without clinical or
histological evidence of any malignancy, was also recruited.
These hospital in- and out-patients suffered a variety of
non-malignant diseases including varicose veins, hernias,
haemorrhoids, mild iron deficiency anaemia, mild hyper-
lipidaemia, benign ovarian cysts (about 30% in total), ten-
sion headaches (-25%), benign skin papillomas (-20%),
benign breast lumps (-5%) and cerebrovascular accidents
('20%). Patients suffering inflammatory pathologies such as
ulcerative colitis, diabetes or asthma or receiving blood trans-
fusions within 3 months of blood sampling were excluded.
Data on hair colour, eye colour, skin type and smoking
history was not available from all controls. Blood (5 ml) was
taken, with appropriate ethics committee approval, into
EDTA and stored at -50°C.
Identification ofGSTTI, CYP2D6 and GSTMI genotypes in
leucocyte DNA
The GSTM1 null, A, B and A/B genotypes were identified
using an amplification refractory mutation system (ARMS)-
based polymerase chain reaction (PCR) approach with
primer sets to intron 6/exon 7 and exon 4/exon 5. The assay
identifies GSTMI*O homozygotes and GSTMI*A/GSTMI*B
heterozygotes and subjects with the GSTM1 A and GSTM1 B
phenotypes. It does not distinguish the GSTMI*O/GSTMI*A
and GSTMI*A/GSTMI*A genotypes or the equivalent
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GSTM1 B genotypes (Fryer et al., 1993). GSTT1 null and
expressing subjects were identified by PCR using the primer
set and reaction conditions described by Pemble et al. (1994)
and Warwick et al. (1994). The two mutant CYP2D6 alleles
(G-*A transition at intron 3/exon 4 and base pair deletion in
exon 5) were identified (Gough et al., 1990; Wolf et al.,
1992). Together these assays are about 90% predictive of
phenotype (Wolf et al., 1992).
Statistical analysis
x2 tests were used to examine for homogeneity between cases
and controls. Since some genotype frequencies were small,
the StatXact-Turbo statistical package was used to obtain
exact P-values. As various factors (CYP2D6 EM, GSTT1
null, GSTM1 null, skin type, gender etc.) were studied, the
influence on susceptibility of each (alone and in combination
in pairs and triplets) was studied by comparing frequency
distributions over the resulting mutually exclusive categories.
The advantage of this approach is that it allows identification
of those factors (alone and in combination) that contribute
most to observed differences between cases and controls.
P-values for the main comparisons (GSTM1, skin type 1,
gender) were not adjusted for multiple comparisons as they
were sufficiently small to remain significant if adjusted using
the Bonferroni correction.
Results
Genotypefrequencies in cases and controls
Table I shows the frequencies of GSTM1 genotypes in cont-
rols, the total BCC group and, patients with single and
multiple BCC. The frequencies of the null, A and B
genotypes were not different though the frequency of
GSTM1 A/B was significantly lower in the multiple BCC
than in the controls (odds ratio 0.29, 95% CI 0.055-0.098)
confirming previous results in 435 of these patients (Heagerty
et al., 1994).
We found no differences in the frequencies of GSTT1
genotypes in controls and the BCC case groups (Table I).
The frequencies of the CYP2D6 EM and HET genotypes in
controls and case groups were also not different though the
difference between the frequency of the PM genotype in
controls and single BCC cases approached significance (Table
I).
Interactions between GSTMI, GSTTI and CYP2D6 genotypes
Interactions between genotypes were studied by comparing
multinomial frequency distributions in mutually exclusive
groups. Comparison of the frequency distributions for com-
binations of the putatively high risk GSTM1 null, GSTT1
null, CYP2D6 EM genotypes (i.e. GSTTI null/GSTM1 null/
CYP2D6 EM and GSTT1 null/GSTM1 null) showed no
significant differences between the controls, patients in the
total, single and multiple BCC groups (data not shown).
Corresponding interactions between GSTM1 A/B and the
putatively protective CYP2D6 PM and GSTT1 positive
genotypes were also examined. Thus, multinomial frequency
distributions for combinations of GSTT1 expressers/GSTM1
A/B and, CYP2D6 PM/GSTM1 A/B in patients with single
and multiple BCC and, controls and patients with multiple
tumours were not significantly different (data not shown).
The differences between frequency distributions of the three
genotypes combined (CYP2D6 PM/GSTT1 expressers/GST-
Ml A/B) in the multiple BCC and single BCC cases and,
multiple BCC and controls approached significance (x26=
11.24, exact P = 0.055 and X25 = 10.06, exact P = 0.067
respectively). These differences largely resulted from
differences in the proportion of subjects with the combination
GSTT1 positive/GSTM1 A/B; thus, the frequency of this
combination was significantly lower (X21 = 6.83, exact P =
0.011) in the multiple BCC group than in controls (data notSusceptibility to multiple BCC
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Tablet CYP2D6, GSTM1 and GSTT1 genotypefrequencies inpatients withsingleandmultiplebasalcell carcinomas of
skin
GSTMJ genotypes
Total BCC (n = 699)
Single BCC (n = 454)
Multiple BCC (n = 245)
Controls (n = 561)
GSTTI genotypes
Total BCC (n = 584)
Single BCC (n = 384)
Multiple BCC (n = 200)
Controls (n = 484)
GSTMI null (%)
376 (53.8)
236 (52.0)
140 (57.1)
306 (54.5)
GSTT1 null (%)
97 (16.6)
57 (14.8)
40 (20.0)
90 (18.6)
GSTM1 A (%)
197 (28.2)
128 (28.2)
69 (28.2)
158 (28.2)
GSTM1 B (%)
108 (15.5)
75 (16.5)
33 (13.5)
74 (13.2)
GSTM1 A/B (%)
18 (2.6)
15 (3.3)
3 (1.2)
23 (4.1)a
GSTTI positive (%)
487 (83.4)
327 (85.2)
160 (80.0)
394 (81.4)
CYP2D6 genotypes
EM (%) HET (%) PM (%)
Total BCC (n = 599) 375 (62.6) 181 (30.2) 43 (7.2)
Single BCC (n = 396) 243 (61.4) 121 (30.6) 32 (8.1)
Multiple BCC (n = 203) 132 (65.0) 60 (29.6) 11 (5.4)
Controls (n = 310) 194 (62.6) 99 (31.9) 17 (5.5)b
Frequency GSTM I A/B in controls and multiple BCC X2] = 4.52; exact P = 0.048. bFrequency CYP2D6 PM in
controls and single BCC X21 = 3.57, Yates corrected P = 0.059.
Table II Multinomial frequency distributions of GSTM1 A/B and CYP2D6 EM
Controls (%) Single BCC (%) Multiple* BCC (%)
GSTMI A/B + CYP2D6 EM 13 (3.4) 8 (2.0) 1 (0.5)**
GSTM1 A/B only 7 (1.8) 5 (1.3) 0 (0)
CYP2D6 EM only 235 (61.7) 235 (59.5) 131 (64.5)
Neither 126 (33.1) 147 (37.2) 71 (35.0)
Total 381 (100) 395 (100) 203 (100)
*Frequency distributions in controls and multiple BCC; X23 = 8.75, P = 0.033. **Frequency
GSTMI A/B + CYP2D6 EM in controls and multiple BCC; X21 = 4.82, exact P = 0.042.
Table III Interactions between male gender and GSTMI null
Controls (%) Single BCC (%) Multiple* BCC (%) Total BCC (%)
GSTMI null + male 79 (31.7) 115 (25.9) 90 (37.5)** 205 (30.0)
Male only 51 (20.5) 117 (26.4) 57 (23.8) 174 (25.4)
GSTM1 null only 62 (24.9) 114 (25.7) 47 (19.6) 161 (23.5)
Neither 57 (22.9) 98 (22.1) 46 (19.1) 144 (21.1}
Total 249 (100) 444 (100) 240 (100) 684 (100)
*Frequency distributions in single and multiple BCC; X23 = 10.49, P = 0.015. **Frequency GSTMI
null + din single and multiple BCC; X2, = 9.44, Yates corrected P = 0.002.
shown). Frequency distributions of GSTM1 A/B/CYP2D6
EM in controls and multiple BCC were significantly different
(Table II). This difference largely resulted from the reduced
frequency of subjects with CYP2D6 EM/GSTM1 A/B in the
multiple BCC group compared with controls (Table II).
Interactions between gender and GSTMI, GSTTI and
CYP2D6 genotypes
The proportion of males in the multiple BCC group (61.3%)
was significantly greater than in controls (47.0%) (X21=
11.85, Yates corrected P = 0.0006) and single BCC (52.2%)
(x2, = 5.29, Yates corrected P = 0.0214, odds ratio 1.45, 95%
CI 1.05-2.00). Interactions between GSTM1 null and male
gender were examined by comparing multinomial frequency
distributions (Table III); distributions in single and multiple
BCC were significantly different and, the frequency of the
combination GSTM1 null/male gender was significantly
greater in patients with multiple tumours (odds ratio 1.72,
95% CI 1.21-2.44).
Interactions between patient characteristics andgenotypes
The proportions of patients in the single and multiple BCC
groups with brown, blue or green eyes were not significantly
different (data not shown).
Frequency distributions of skin types 1-5 in the single and
multiple BCC cases were also not significantly different
(Table IV-VI). Considering skin type in terms of no protec-
tion (type 1) and variable protection to UV (types 2-5), we
compared multinomial frequency distributions of GSTM1
null with skin type 1 in the patients with single and multiple
BCC. The proportion of subjects with these factors was
significantly greater in the multiple BCC group than in those
with a single BCC (Table IV-VI). Thus, the frequency dist-
ributions of GSTM1 null/skin type 1 were significantly
different and, the proportion of subjects who were GSTM1
null with skin type 1 was significantly greater (Table IV-VI;
odds ratio 3.25, 95% CI 1.30-8.27) in the multiple BCC
group. We examined the data for interactions between
GSTM1 null/skin type 1/male gender by comparing multi-
nomial frequency distributions of these factors in the single
and multiple BCC groups. The distributions were almost
significantly different (Table IV-VI). No significant interac-
tions between GSTTI null or CYP2D6 EM and skin type 1
were identified (data not shown).
Interactions between smoking andgenotypes
The proportion of cases who were current smokers or ever
smokers was not significantly different in the single and
multiple BCC groups. Comparisons of multinomial frequencySusceptibility to multiple BCC
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Table IV Skin type frequencies in single and multiple BCC
Skin type 1 2 3 4 5
Single BCC (n = 302) 34 94 98 59 17
(11.3%) (31.1%) (32.5%) (19.5%) (5.6%)
Multiple BCC (n = 162) 26 50 54 27 5
(16.0%) (30.9%) (33.3%) (16.7%) (3.1%)
Table V Frequency distributions of GSTMI null and skin type 1
Controls (%) Single BCCa (%) Multiple BCC (%)
GSTM1 null + type 1 2 (4.4) 9 (3.3) 15 (lO.O)b
Type 1 only 0 (0) 20 (7.4) 7 (4.7)
GSTMI null only 24 (53.0) 131 (48.2) 66 (44.0)
Neither 19 (42.2) 112 (41.2) 62 (41.3)
Total 45 (100) 272 (100) 150 (100)
aFrequency distributions in single and multiple BCC; X23 = 9.06; P = 0.0285.
bFrequency GSTM1 null + skin type 1 in single v multiple BCC; X21 = 6.87; P = 0.009.
Table VI Interactions between GSTM I null, skin type I and male gender
Single BCCO (%) Multiple BCC (%)
GSTMI null + type 1 + male 5 (1.9) 7 (4.8)
GSTMI null + type 1 only 5 (1.9) 7 (4.8)
Type 1 + male only 10 (3.7) 3 (2.0)
GSTM1 null + male only 60 (22.2) 44 (29.9)
Male only 63 (23.3) 34 (23.1)
Skin type I only 10 (3.7) 4 (2.7)
GSTM1 null only 69 (25.6) 22 (15.0)
None 48 (17.8) 26 (17.7)
a Frequency distributions in single and multiple BCC; X27= 13.88, exact
P= 0.051.
distributions of smoking with each of the GSTM1 null,
GSTT1 null and CYP2D6 EM genotypes identified no diff-
erences between patients with single and multiple tumours
(data not shown).
Discussion
The role of factors other than UV in the pathogenesis of
BCC is evident from work using a variety of experimental
approaches (Heagerty et al., 1994; Karagas et al., 1994; Wei
et al., 1994; McHenry et al., 1995). We have described fur-
ther studies on the influence of allelism at loci encoding
phase I and II detoxifying enzymes on susceptibility to this
tumour. Genotype frequencies in controls have been com-
pared with those in the total BCC group and patients with
single and multiple carcinomas. Interactions with other
relevant factors such as skin type, gender and smoking have
also been studied.
The present study confirms, in a substantially larger
patient group, previous work from this laboratory showing
the heterozygote GSTM1 A/B genotype is associated with a
reduced risk of multiple BCC (Heagerty et al., 1994). The
mechanism for this protective effect against multiple BCC is
unclear but is presumably related to the ability of these
enzymes to catalyse the metabolism of a variety of products
of oxidative stress formed after exposure to UV and/or cons-
tituents of cigarette smoke and other environmental poll-
utants (Ketterer et al., 1993). The finding that protection is
associated with GSTM1 A/B but not GSTM1 A or GSTM1 B
(largely GSTMI*O heterozygotes) suggests a gene dosage
effect that is specific to multiple BCC but not other skin
malignancies such as squamous cell cancer or malignant
melanoma. No protective effect for GSTT1 was identified,
although the genotyping assay used cannot differentiate
GSTTI*A/GSTTI*A homozygotes and GSTTI*O/GSTTI*A
heterozygotes. It is possible the minority of subjects (about
30%) with two expressed alleles are protected but this effect
is diluted by the larger number of GSTTI*O heterozygotes.
We also found no differences in frequency distributions of
CYP2D6 genotypes in the cases and controls though the
frequency of CYP2D6 PM was greater in patients with single
BCC than in controls.
Recent studies showing the interactive effects of GSTM1
and CYPlAl genotypes suggest that the influence of detox-
ifying enzymes in mediating cancer risk will depend on
allelism at other relevant loci (Nakachi et al., 1993; Warwick
et al., 1994). We identified no significant interactions between
the putatively poor detoxification genotypes, GSTM1 null,
GSTT1 null and CYP2D6 EM but did find significant
differences between controls and patients with multiple BCC
in the frequency of the combinations GSTM1 A/B with
CYP2D6 EM and, GSTM1 A/B with GSTT1 expressers.
The importance of GSTM1 was emphasised by the finding
that the frequency of the combination GSTM1 null/skin type
I was significantly increased in patients with multiple BCC
compared with those with a single tumour. Skin type is an
arbitrary and subjective classification of individual response
to UV. The classification of skin type 1 defines an extreme
sensitivity to UV, which results in an inflammatory response
but no pigmentary response (Fitzpatrick et al., 1988). Our
results show GSTM1 null alone is not a significant deter-
minant of development of multiple BCC but the influence of
skin type 1 is synergistic, such that in combination they are a
significant predisposing factor to multiple BCC, possibly
because these individuals are relatively less able to cope with
the chemical products of UV or those of the resulting
inflammation.
Significant interactions between GSTM1 null and male
gender were also identified. The incidence of non-melanoma
skin cancer is higher in men than women and Karagas et al.
(1994) showed that in males with a prior tumour, the risk of
a further BCC is 50% greater than in women. We also found
a greater proportion of men in the multiple tumour group
than in the single BCC or control groups. The mechanism for
the observed interactions between GSTM1 null and gender
and skin type 1 is unclear. Females may be relatively pro-
tected because oestrogens appear to stimulate melanin prod-
uction both in vivo and in vitro (McLeod et al., 1994).Susceptibility to multiple BCC
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Previous studies have failed to demonstrate an association
between smoking and BCC or, smoking and risk of further
tumours (Hunter et al., 1990; Karagas et al., 1994). As the
number of controls from whom a reliable smoking history
could be obtained was limited, we did not compare the
proportions of ever/never smokers in the case groups with
those in controls. However, it is noteworthy that the propor-
tion of smokers in our BCC case group was significantly
greater (P<0.0002) than that found by the Health Promo-
tion Service of the North Staffordshire Hospital during a
survey of 1957 unmatched, local adults (465, 23.9%) ques-
tioned during 1993. In agreement with previous findings our
data showed that smoking alone did not increase the risk of
multiple tumours (Karagas et al., 1994). We have now shown
that smoking does not influence risk of multiple tumours
even in combination with putatively poor detoxification
genotypes.
A better understanding of factors that predispose to single
and multiple BCC will help devise preventative strategies for
what is an increasing public health problem. While we
identified few factors that influence the development of a
single BCC, factors that mediate susceptibility to multiple
tumours were found. The importance of GSTM1 has been
emphasised, both the protective effect of GSTM1 A/B and
the increased risk associated with the combination of skin
type 1 and male gender with GSTM1 null. The influence of
GSTT1 and CYP2D6 appeared to be less significant except
in combination with GSTM1 A/B. We believe that our
results are compatible with the view that development of
multiple tumours is not merely determined by time but
rather, certain patients have a genetically mediated increased
susceptibility (Karagas et al., 1994). We also presume that
our data have underestimated the differences between
patients with single and multiple tumours as some patients
with single BCC are likely to eventually develop further
tumours. There are no data from British patients, although
local clinical experience suggests that the frequency of multi-
ple tumours is lower than that found in American studies.
The significant interaction between GSTM1 and skin type 1
indicates that other polymorphic genes that influence this
phenotype, such as those determining melanin production
and the immune response, are promising candidates.
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